Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational benefits to patients with life-threatening diseases, ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

The investigators also reported that LTI-03 helped preserve alveolar epithelial type II (AT2) progenitor cells, which are essential for lung repair and regeneration. Current IPF therapies primarily ...

A 3D illustration of human lungs. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug ...

Orphan drug designation speaks to the importance of developing new treatments for debilitating rare diseases like IPF, for which treatment options are limited,” said Margrethe Sørgaard, Calluna Pharma ...

Ingelheim, Germany/Ridgefield, Connecticut, U.S. “This milestone represents a new era in the treatment of IPF, a rare and debilitating chronic condition that worsens lung function. Nerandomilast has ...

The news of Diane Ladd’s death at 89 has brought attention to a rare but serious lung condition. The legendary actress, known ...

Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings ...

The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...